Monopar Therapeutics Inc. announced on September 23, 2025, the pricing of an underwritten registered offering of common stock and pre-funded warrants, expected to generate gross proceeds of approximately $100 million after an anticipated stock repurchase.
The offering includes 1,034,433 shares of common stock priced at $67.67 per share, and pre-funded warrants to purchase 960,542 shares at $67.669 per pre-funded warrant. The company intends to use up to $35 million of the proceeds to repurchase shares of its common stock held by Tactic Pharma, LLC at $63.6098 per share.
The remaining net proceeds from the offering are designated for general corporate purposes, including research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital. The offering is expected to close around September 25, 2025, subject to customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.